New MenaQ7 patents granted to NattoPharma in US, Israel and Australia

6b8015c8-ad96-4c8c-a133-ab76615dc355articleimage.jpg

08 Nov 2017 --- NattoPharma ASA has successfully secured patents in Israel, the US and Australia for its “nature-identical synthesis” creating MenaQ7 PharmaPure Vitamin K2 as MK-7, adding further to the company’s patent portfolio.

“These patents underline our position as the leader in the vitamin K2 market,” Kjetil Ramsøy, NattoPharma Chief Financial Officer, tells NutritionInsight. “Having the most clinically validated vitamin K2 as MK-7 available today, and the only all-trans nature-identical synthetic available that is free of cis-isomers, this will give our partners the validation they need to ensure they are serving their customers the best possible product.”

Global success with patents
NattoPharma details the company’s progress with patents:

  • Israel: On July 31, 2017, patent #238199 “Process for preparation of MK-7 type of Vitamin K2” was granted.
  • US: On August 28, 2017, Notice of Allowance for patent #14/435,260 “Process for preparation of MK-7 type vitamin K2” was issued.
  • Australia: On July 5, 2017, Notice of Acceptance (NoA) was issued for patent #2013330517 “process for preparation of MK-7 type of vitamin K2.” This NoA was published on July 20.

“This unique patented process results in the world’s only truly all-trans synthetic vitamin K2 as MK-7,” says William Sommer, NattoPharma’s Vice President of Global Development & Regulatory. “Our material is of the highest quality and superior to anything else on the market, so much so that it is currently being utilized in two studies sponsored by the traditional medical community.”

“These studies are evidence that the medical community recognizes the difference a vitamin can make for human health, and in selecting MenaQ7 PharmaPure, they want to use the purest, all-trans material for future further confirmation and discovery of health benefits,” he continues. “This technology also ensures supplement providers deliver the MK-7 with the health benefits consumers desire.”

Sommer adds that NattoPharma has made significant intellectual and monetary investments technologies in, and that the company is committed to actively monitor market developments to protect the company’s intellectual property rights throughout their lifespan.

“The approval of these patents represents another milestone for NattoPharma and our partners,” concludes Sommer. “This further strengthens NattoPharma’s global intellectual property rights platform and improves our competitive position within the food supplement market.”

“We see a very positive development in the interest in vitamin K2, which is also supported by our global growth over the last couple of years,” Ramsøy notes to NutritionInsight. “We expect this to continue in the coming years as the knowledge about the benefits of Vitamin K2 grows even more in the consumer market.”

There are also plans to obtain patents for MenaQ7 in further countries. “Patents are currently pending in a number of different jurisdictions, both for the synthetic production patent for PharmaPure, as well as for different health claims related to the use of vitamin K2 as a dietary supplement,” Ramsøy explains.

By Paul Creasy

Related Articles

Nutrition & Health News

Energetic growth: Energy boosters add pep to the nutritional space’s step

11 Dec 2017 --- Busy schedules can cause consumers to go through an “energy crisis” – prompting their desire to reach for products that might offer some support to their energy levels. Energy boosters are certainly showing signs of growth in all regions tracked by Innova Market Insights. A CAGR in supplement launches of +208.8 percent in South America from 2012 to 2016 is particularly noteworthy, while Europe is top of the pile worldwide with 28.8 percent of its supplement launches having an energy claim in 2016 and its CAGR amounting to a strong +86.7 percent.

Business News

Lakeview Equity invests in nutritional solutions provider NutriScience Innovations

11 Dec 2017 --- Lakeview Equity Partners, LLC, a US$40 million Milwaukee, US-based private equity fund, has invested in NutriScience Innovations, LLC, based in Trumbull, Connecticut, US. NutriScience is a cGMP-certified global supplier of nutritional and functional ingredients to companies that manufacture nutraceutical, pharmaceutical, food and beverage, and dietary products.

Business News

Consuming sugary drinks during pregnancy may increase asthma risk in mid-childhood

08 Dec 2017 --- Children between the ages of 7 and 9 may be at greater risk for developing asthma if they consumed high amounts of fructose in early childhood or their mothers drank a lot of sugar-sweetened beverages while pregnant, according to new research published online in the Annals of the American Thoracic Society.

Business News

New Biopolis probiotic mix helps reduce topical steroid use by atopic dermatitis patients

07 Dec 2017 --- Biopolis, majority owned by agricultural processor and food ingredient provider Archer Daniels Midland Company (ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients. The clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patients.

Nutrition & Health News

Ingredion carbohydrate shows positive glycemic response and energy release results

06 Dec 2017 --- Ingredient solutions provider Ingredion Incorporated has announced the results of a new clinical study into the sustained energy effects of the Sustra 2434 slowly digestible carbohydrate. The study, published in the peer-reviewed scientific journal Nutrients, is the first to characterize physiological responses to the slowly digestible starch (SDS) in two different foods and found that it lowers glycemic response and produces a steadier energy release.

More Articles
URL : http://www.nutritioninsight.com:80/news/new-menaq7-patents-granted-to-nattopharma-in-us-israel-and-australia.html